Cart
0

Human Insulin Market by Types (Traditional Human Insulin, Premixed Traditional, Intermediate Acting, Modern Human Insulin, Premixed Modern, Long Acting, Rapid Acting) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Get 20% Free Customization In This Report
LI_18417
Pages: NA
Jan 2019 | 4155 Views
 
Author's : NA
Tables: NA
Charts: NA
 

Insulin regulates fat and carbohydrate metabolism in the body. It is a peptide hormone, which is secreted in the pancreas by beta cells of the islets of Langerhans and it helps to regulate the glucose metabolism. It causes skeletal muscle cells and fat tissues to absorb glucose from the blood. The global human insulin market is expected to grow at healthy CAGR during the forecast period due to high prevalence of diabetes, worldwide. In-depth analysis of the global human insulin market focuses on various aspects of the market such as market trends, market drivers, restraints and opportunities. Competitive landscape section focuses on key leaders within the global human insulin market and their major growth strategies. Detailed analysis of segments helps in understanding market dynamics and would be beneficial for market professionals.

The growth of global human insulin market is primarily attributed to rising prevalence of diabetes. The factors that contribute to growing number of diabetic patient globally include changes in lifestyles, growing number of obese as well as geriatric population and inadequate healthcare services. Favorable government policies and technological advances such as innovation of insulin pens have also fueled the growth of this market. However, cost of production, manufacturing complexities and critical regulatory requirements for the approval of biotechnology derived products are the factors that could hinder the growth of global human insulin market. Pipeline insulin products and untapped emerging economies are the promising opportunities for the manufacturers of global human insulin.

Global Human Insulin Market by Types

The global human insulin market is segmented by product type into Traditional and Modern Human Insulin. Traditional Human Insulin is segmented as Premixed, Intermediate Acting and Short Acting Human Insulin, whereas Modern Human Insulin includes Premixed, Long Acting and Rapid Acting types. Long acting modern insulin and premixed modern insulin are the fastest growing categories of this segment.  

Global Human Insulin Market by Brands

According to the brands available into the market, the global human insulin market is classified as traditional and modern human insulin brands. Traditional brands include Humulin, Actrapid and Insuman, whereas, modern brands include Humalog, Novomix, Novorapid, Lantus, Levemir and Apidra. Over the past few years, biosimilars has gained popularity in comparison to branded drugs. Basalog, Wosulin and Glaritus are the biosimilars available in Asia-Pacific region. Amongst traditional and modern brands, Lantus holds the largest market share, whereas, Levemir and Apidra are the fastest growing insulin drugs. 

Global Human Insulin Market by Geography

Geographically, global human insulin market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America dominates the global human insulin market owing to high prevalence of diabetes and technological advances in effective insulin delivery. Asia-Pacific and LAMEA are the fastest growing geographic segments due to high diabetes incidences, government support and improving healthcare conditions.  

 
Competitive Landscape

Eli Lilly, GlaxoSmithCline, Biocon, Sanofi Aventis, Julphar, Novo Nordisk, SemBioSys, and Wockhardt are some of the key players of global human insulin market. Manufacturers are focusing to develop the advanced techniques of insulin delivery to gain the competitive advantage. Development of biosimilars is a booming trend in global human insulin market and Wockhardt and Biocon have launched their biosimilars products in Asia-Pacific region.

High Level Analysis 

The study identifies the potential market drivers, challenges and trends. Competitive landscape section provides explicit information of the big players ruling the global human insulin market, their operating strategies, new launches, pipeline products and clinical trials. Porter’s Five Forces analysis has been used to determine the attractiveness of global human insulin market. Large pool of diabetic population and high cost of technology required to manufacture innovative insulin delivery devices are the factors that tend to increase the supplier’s bargaining power. High cost of down streaming process and manunufacturing complexities limit the new players in entering the market. Industrial rivalry is intense due to patent expiration of major brands and growing demand for biosimilars products.

KEY BENEFITS

This report offers the following benefits in particular:

  • Comprehensive coverage of global human insulin market along with disease overview, market trends, drivers and restraints
  • Thorough attention is given to leading company portfolios, pipeline research, new launches and competitive landscape of top players
  • Explicit information on current clinical trials and R&D activities would be beneficial to understand the future market trends  
  • Insightful analysis of different segments helps to recognize and capitalize future opportunities within global human insulin market

KEY DELIVERABLES

The global human insulin market is segmented into three major categories such as, Product Type, Brand and Geography. 

MARKET BY TYPES

  • Traditional Human Insulin   
    • Premixed Traditional 
    • Intermediate Acting
    • Short Acting
  • Modern Human Insulin   
    • Premixed Modern
    • Long Acting
    • Rapid Acting

MARKET BY BRAND

  • Traditional Human Insulin Brands
    • Humulin  
    • Actrapid
    • Insuman
  • Modern Human Insulin Brands
    • Humalog
    • Novomix
    • Novorapid
    • Lantus
    • Levemir
    • Apidra

MARKET BY GEOGRAPHY

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS/ TOP PLAYER POSITIONING, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 HUMAN INSULIN (HI) MARKET, BY PRODUCT TYPE

4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. HI DRUGS
4.2.1. Key market trends
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. HI DELIVERY DEVICES
4.3.1. Key market trends
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

Chapter: 5 HUMAN INSULIN (HI) MARKET, BY DRUG TYPE

5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. HI BIOLOGICS
5.2.1. Market size and forecast, by type
5.2.1.1. Short-Acting Biologics
5.2.1.1.1. Market size and forecast
5.2.1.2. Intermediate Acting Biologics
5.2.1.2.1. Market size and forecast
5.2.1.3. Premixed Biologics
5.2.1.3.1. Market size and forecast
5.2.2. Market size and forecast, by region
5.2.3. Market analysis, by country
5.3. HI BIOSIMILARS AND ANALOGS
5.3.1. Market size and forecast, by type
5.3.1.1. Long-Acting Biosimilars
5.3.1.1.1. Market size and forecast
5.3.1.2. Rapid Acting Biosimilars
5.3.1.2.1. Market size and forecast
5.3.1.3. Premixed Biosimilars
5.3.1.3.1. Market size and forecast
5.3.2. Market size and forecast, by region
5.3.3. Market analysis, by country

Chapter: 6 HUMAN INSULIN (HI) MARKET, BY DRUG BRAND

6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. HI BIOLOGICS
6.2.1. Market size and forecast, by type
6.2.1.1. Actrapid, Mixtard, and Insulatard
6.2.1.1.1. Market size and forecast
6.2.1.2. Humulin
6.2.1.2.1. Market size and forecast
6.2.1.3. Insuman
6.2.1.3.1. Market size and forecast
6.2.2. Market size and forecast, by region
6.2.3. Market analysis, by country
6.3. HI BIOSIMILARS AND ANALOGS
6.3.1. Market size and forecast, by type
6.3.1.1. Lantus
6.3.1.1.1. Market size and forecast
6.3.1.2. Novorapid &Novolog
6.3.1.2.1. Market size and forecast
6.3.1.3. Humalog
6.3.1.3.1. Market size and forecast
6.3.1.4. Others
6.3.1.4.1. Market size and forecast
6.3.2. Market size and forecast, by region
6.3.3. Market analysis, by country

Chapter: 7 HUMAN INSULIN (HI) MARKET, BY DELIVERY DEVICE

7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. SYRINGES
7.2.1. Market size and forecast, by region
7.2.2. Market analysis, by country
7.3. PENS
7.3.1. Market size and forecast, by type
7.3.1.1. Reusable Pens
7.3.1.1.1. Market size and forecast
7.3.1.2. Disposable Pens
7.3.1.2.1. Market size and forecast
7.3.2. Market size and forecast, by region
7.3.3. Market analysis, by country
7.4. PEN NEEDLES
7.4.1. Market size and forecast, by type
7.4.1.1. Standard Pen Needles
7.4.1.1.1. Market size and forecast
7.4.1.2. Safety Pen Needles
7.4.1.2.1. Market size and forecast
7.4.2. Market size and forecast, by region
7.4.3. Market analysis, by country

Chapter: 8 HUMAN INSULIN (HI) MARKET, BY APPLICATION

8.1. OVERVIEW
8.1.1. Market size and forecast
8.2. TYPE I DIABETES
8.2.1. Market size and forecast, by region
8.2.2. Market analysis, by country
8.3. TYPE II DIABETES
8.3.1. Market size and forecast, by region
8.3.2. Market analysis, by country

Chapter: 9 HUMAN INSULIN (HI) MARKET, BY REGION

9.1. OVERVIEW
9.2. NORTH AMERICA
9.2.1. Key market trends
9.2.2. Market size and forecast, by country
9.2.3. U.S. market size and forecast
9.2.3.1.1. U.S. HI market, by product type
9.2.3.1.2. U.S. HI market, by drug type
9.2.3.1.3. U.S. HI market, by drug brand
9.2.3.1.4. U.S. HI market, by delivery device
9.2.3.1.5. U.S. HI market, by application
9.2.4. Canada market size and forecast
9.2.4.1.1. Canada HI market, by product type
9.2.4.1.2. Canada HI market, by drug type
9.2.4.1.3. Canada HI market, by drug brand
9.2.4.1.4. Canada HI market, by delivery device
9.2.4.1.5. Canada HI market, by application
9.2.5. Mexcio market size and forecast
9.2.5.1.1. Mexico HI market, by product type
9.2.5.1.2. Mexico HI market, by drug type
9.2.5.1.3. Mexico HI market, by drug brand
9.2.5.1.4. Mexico HI market, by delivery device
9.2.5.1.5. Mexico HI market, by application
9.2.6. North America HI market, by product type
9.2.7. North America HI Market, by drug type
9.2.8. North America HI market, by drug brand
9.2.9. North America HI Market, by delivery device
9.2.10. North America HI market, by application
9.3. EUROPE
9.3.1. Key market trends
9.3.2. Market size and forecast, by country
9.3.3. Germany market size and forecast
9.3.3.1.1. Germany HI market, by product type
9.3.3.1.2. Germany HI market, by drug type
9.3.3.1.3. Germany HI market, by drug brand
9.3.3.1.4. Germany HI market, by delivery device
9.3.3.1.5. Germany HI market, by application
9.3.4. France market size and forecast
9.3.4.1.1. France HI market, by product type
9.3.4.1.2. France HI market, by drug type
9.3.4.1.3. France HI market, by drug brand
9.3.4.1.4. France HI market, by delivery device
9.3.4.1.5. France HI market, by application
9.3.5. UK market size and forecast
9.3.5.1.1. UK HI market, by product type
9.3.5.1.2. UK HI market, by drug type
9.3.5.1.3. UK HI market, by drug brand
9.3.5.1.4. UK HI market, by delivery device
9.3.5.1.5. UK HI market, by application
9.3.6. Italy market size and forecast
9.3.6.1.1. Italy HI market, by product type
9.3.6.1.2. Italy HI market, by drug type
9.3.6.1.3. Italy HI market, by drug brand
9.3.6.1.4. Italy HI market, by delivery device
9.3.6.1.5. Italy HI market, by application
9.3.7. Spain market size and forecast
9.3.7.1.1. Spain HI market, by product type
9.3.7.1.2. Spain HI market, by drug type
9.3.7.1.3. Spain HI market, by drug brand
9.3.7.1.4. Spain HI market, by delivery device
9.3.7.1.5. Spain HI market, by application
9.3.8. Rest of Europe market size and forecast
9.3.8.1.1. Rest of Europe HI market, by product type
9.3.8.1.2. Rest of Europe HI market, by drug type
9.3.8.1.3. Rest of Europe HI market, by drug brand
9.3.8.1.4. Rest of Europe HI market, by delivery device
9.3.8.1.5. Rest of Europe HI market, by application
9.3.9. Europe HI market, by product type
9.3.10. Europe HI Market, by drug type
9.3.11. Europe HI market, by drug brand
9.3.12. Europe HI Market, by delivery device
9.3.13. Europe HI market, by application
9.4. ASIA-PACIFIC
9.4.1. Key market trends
9.4.2. Market size and forecast, by country
9.4.3. Japan market size and forecast
9.4.3.1.1. Japan HI market, by product type
9.4.3.1.2. Japan HI market, by drug type
9.4.3.1.3. Japan HI market, by drug brand
9.4.3.1.4. Japan HI market, by delivery device
9.4.3.1.5. Japan HI market, by application
9.4.4. China market size and forecast
9.4.4.1.1. China HI market, by product type
9.4.4.1.2. China HI market, by drug type
9.4.4.1.3. China HI market, by drug brand
9.4.4.1.4. China HI market, by delivery device
9.4.4.1.5. China HI market, by application
9.4.5. India market size and forecast
9.4.5.1.1. India HI market, by product type
9.4.5.1.2. India HI market, by drug type
9.4.5.1.3. India HI market, by drug brand
9.4.5.1.4. India HI market, by delivery device
9.4.5.1.5. India HI market, by application
9.4.6. Australia market size and forecast
9.4.6.1.1. Australia HI market, by product type
9.4.6.1.2. Australia HI market, by drug type
9.4.6.1.3. Australia HI market, by drug brand
9.4.6.1.4. Australia HI market, by delivery device
9.4.6.1.5. Australia HI market, by application
9.4.7. South Korea market size and forecast
9.4.7.1.1. South Korea HI market, by product type
9.4.7.1.2. South Korea HI market, by drug type
9.4.7.1.3. South Korea HI market, by drug brand
9.4.7.1.4. South Korea HI market, by delivery device
9.4.7.1.5. South Korea HI market, by application
9.4.8. Rest of Asia-Pacific market size and forecast
9.4.8.1.1. Rest of Asia-Pacific HI market, by product type
9.4.8.1.2. Rest of Asia-Pacific HI market, by drug type
9.4.8.1.3. Rest of Asia-Pacific HI market, by drug brand
9.4.8.1.4. Rest of Asia-Pacific HI market, by delivery device
9.4.8.1.5. Rest of Asia-Pacific HI market, by application
9.4.9. Asia-Pacific HI market, by product type
9.4.10. Asia-Pacific HI Market, by drug type
9.4.11. Asia-Pacific HI market, by drug brand
9.4.12. Asia-Pacific HI Market, by delivery device
9.4.13. Asia-Pacific HI market, by application
9.5. LAMEA
9.5.1. Key market trends
9.5.2. Market size and forecast, by country
9.5.3. Brazil market size and forecast
9.5.3.1.1. Brazil HI market, by product type
9.5.3.1.2. Brazil HI market, by drug type
9.5.3.1.3. Brazil HI market, by drug brand
9.5.3.1.4. Brazil HI market, by delivery device
9.5.3.1.5. Brazil HI market, by application
9.5.4. Saudi Arabia market size and forecast
9.5.4.1.1. Saudi Arabia HI market, by product type
9.5.4.1.2. Saudi Arabia HI market, by drug type
9.5.4.1.3. Saudi Arabia HI market, by drug brand
9.5.4.1.4. Saudi Arabia HI market, by delivery device
9.5.4.1.5. Saudi Arabia HI market, by application
9.5.5. South Africa market size and forecast
9.5.5.1.1. South Africa HI market, by product type
9.5.5.1.2. South Africa HI market, by drug type
9.5.5.1.3. South Africa HI market, by drug brand
9.5.5.1.4. South Africa HI market, by delivery device
9.5.5.1.5. South Africa HI market, by application
9.5.6. Rest of LAMEA market size and forecast
9.5.6.1.1. Rest of LAMEA HI market, by product type
9.5.6.1.2. Rest of LAMEA HI market, by drug type
9.5.6.1.3. Rest of LAMEA HI market, by drug brand
9.5.6.1.4. Rest of LAMEA HI market, by delivery device
9.5.6.1.5. Rest of LAMEA HI market, by application
9.5.7. LAMEA HI market, by product type
9.5.8. LAMEA HI Market, by drug type
9.5.9. LAMEA HI market, by drug brand
9.5.10. LAMEA HI Market, by delivery device
9.5.11. LAMEA HI market, by application

Chapter: 10 COMPANY PROFILES

10.1. ALBIREO PHARMA, INC.
10.1.1. Operating business segments
10.1.2. Business performance
10.1.3. Key strategic moves and developments
10.2. B. BRAUN MELSUNGEN AG
10.2.1. Operating business segments
10.2.2. Business performance
10.2.3. Key strategic moves and developments
10.3. BECTON, DICKINSON AND COMPANY
10.3.1. Operating business segments
10.3.2. Business performance
10.3.3. Key strategic moves and developments
10.4. BIOCON LIMITED
10.4.1. Operating business segments
10.4.2. Business performance
10.4.3. Key strategic moves and developments
10.5. SANOFI S.A.
10.5.1. Operating business segments
10.5.2. Business performance
10.5.3. Key strategic moves and developments
10.6. WOCKHARDT LIMITED
10.6.1. Operating business segments
10.6.2. Business performance
10.6.3. Key strategic moves and developments
10.7. JULPHAR
10.7.1. Operating business segments
10.7.2. Business performance
10.7.3. Key strategic moves and developments
10.8. YPSOMED HOLDING AG
10.8.1. Operating business segments
10.8.2. Business performance
10.8.3. Key strategic moves and developments
10.9. ELI LILLY AND COMPANY
10.9.1. Operating business segments
10.9.2. Business performance
10.9.3. Key strategic moves and developments
10.10. NOVO Nordisk A/S
10.10.1. Operating business segments
10.10.2. Business performance
10.10.3. Key strategic moves and developments

 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request TOC/Sample

Request Customization

Request TOC/Sample

OR

Purchase Full Report of
Human Insulin Market- Global Opportunity Analysis and Industry Forecast, 2014 - 2022

  • Online Only
  • $3456 $3111
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840 $3456
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370 $4833
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450 $5805
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995 $8096
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo